location： Home > Products > Signaling Pathways > Epigenetics > JAK

Itacitinib (INCB-039110)

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V0065

CAS #: 1334298-90-6Purity ≥98%

Description: Itacitinib (also known as INCB39110) is a potent, selective and orally bioavailable inhibitor of JAK1 (Janus-associated kinase 1) with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2 (IC50 for JAK1, 2, 3, and TYK2 are 2, 63, >2000, and 795 nM, respectively). It has potential antineoplastic activity and is currently in Phase II clinical trials for the treatment of myelofibrosis, rheumatoid arthritis and plaque psoriasis. Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are critical in cytokine signalling and are strongly linked to both cancer and inflammatory diseases. For example, constitutive activation of the inflammation-related IL-6/JAK/STAT3 signaling pathway has been reported in pancreatic tumors and has been suggested to be a poor prognostic factor for overall survival in patients with advanced disease.

References: Haematologica. 2017 Feb;102(2):327-335; Expert Opin Ther Pat. 2017 Feb;27(2):127-143; AACR; Cancer Res. 2015, 75(15 Suppl).

Related CAS: 1334302-63-4 (adipate salt) 1334298-90-6 (free base)

Customer Validation

Top Publications Citing Invivochem Products

Bulletin Board Product Catalog 2023

Bulletin Board

详情页公告 Guide to Product Handling

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	553.51
Formula	C26H23F4N9O
CAS No.	1334298-90-6 (free base);
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: >90 mg/mL
	Water: <1 mg/mL
	Ethanol: >90 mg/mL
Chemical Name	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl) piperidin-4-yl)azetidin-3-yl)acetonitrile
Synonyms	Itacitinib; INCB039110; INCB-039110; INCB 039110; INCB39110; INCB 39110; INCB-39110
SMILES Code	N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

In Vitro	In vitro activity: Itacitinib (also known as INCB39110) is a potent, selective and orally bioavailable inhibitor of JAK1 (Janus-associated kinase 1) with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2 (IC50 for JAK1, 2, 3, and TYK2 are 2, 63, >2000, and 795 nM, respectively). It has potential antineoplastic activity and is currently in Phase II clinical trials for the treatment of myelofibrosis, rheumatoid arthritis and plaque psoriasis. Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are critical in cytokine signalling and are strongly linked to both cancer and inflammatory diseases. Kinase Assay: Itacitinib has >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2 (IC50 for JAK1, 2, 3, and TYK2 are 2, 63, >2000, and 795 nM, respectively).
In Vivo	Itacitinib is able to inhibit tumor growth in human pancreatic xenograft models in mice at clinically relevant doses, both as monotherapy and in combination with cytotoxic agents such as gemcitabine.
Animal model	Human pancreatic xenograft models in mice
Formulation & Dosage	N/A
References	Haematologica. 2017 Feb;102(2):327-335; Expert Opin Ther Pat. 2017 Feb;27(2):127-143; AACR; Cancer Res. 2015, 75(15 Suppl).

These protocols are for reference only. InvivoChem does not independently validate these methods.

Lot#: V006501,Purity ≥98%
COA
MSDS
NMR

Itacitinib

Treatment effects on total symptom score (TSS). Haematologica. 2017 Feb;102(2):327-335.

Itacitinib

Treatment effects on spleen volume. Haematologica. 2017 Feb;102(2):327-335.

Itacitinib

Mean hemoglobin level and platelet count over time by dose cohort. Haematologica. 2017 Feb;102(2):327-335.

Home Prev Next Last page / pices

发评论

Your information is safe with us. * Required Fields.

Product name

Cat

Applicant name

Email address

Phone number

Organization name

Country

Requested quantity

Remarks